Transdermal menopausal hormone therapy: Delivery through skin changes the rules

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1489-1499

  Buster, John E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Estradiol; Gels; Hot flashes; Patches; Sexual desire; Spray; Testosterone; Transdermal

Indexed keywords

ANDROGEN; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; DIVGEL; ESTRADIOL; ESTRATEST; ESTROGEN; HIGH DENSITY LIPOPROTEIN; HORMONE BINDING PROTEIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN; PRASTERONE SULFATE; SOMATOMEDIN; TESTOSDERM; TESTOSTERONE; UNCLASSIFIED DRUG;

ABDOMINAL FAT; AEROSOL; AMNESIA; BODY COMPOSITION; BODY FAT; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; GEL; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; IMPLANT; INSULIN RESISTANCE; INTERMETHOD COMPARISON; LEAN BODY WEIGHT; LIPID STORAGE; MENOPAUSE; METABOLIC SYNDROME X; MICROVASCULARIZATION; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE; PREVALENCE; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SKIN IRRITATION; TRANSDERMAL PATCH; VASOMOTOR DISORDER; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; TESTOSTERONE;

EID: 77952697219     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003774098     Document Type: Review

References (67)

1. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986;314(25):1615-1620
2. Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? J Clin Endocrinol Metab 1998;83(11):3920-3924
3. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35(9 Suppl):18S-24S
4. Shifren JL. Androgens, estrogens, and metabolic syndrome at midlife. Menopause 2009;16(2):226-228
5. Shifren JL, Desindes S, Mcllwain M, et al. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14(6):985-994
6. Shifren JL, Rifai N, Desindes S, et al. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reative protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin endocrinol Metab 2008;93(5):1702-1710
7. Bachmann GA. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005;50(3):155-165
8. Rapkin AJ. Vasomotor symptoms in menopause: physiologic conditions and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196(2):97-106
9. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med 2006;3(2):212-222
10. Tataryn IV, Lomax P, Meldrum DR, et al. Objective techniques for the assessment of postmenopausal hot flashes. Obstet Gynecol 1981;57(3):340-344
11. Sturdee DW. The menopausal hot flush----anything new? Maturitas 2008;60(3-4):257
12. Andrikoula M, Prelevic G. Menopausal hot flushes revisited. Climacteric 2009;12(1):3-15
13. Buster JE. Low-dose estradiol spray: a novel treatment for vasomotor instability in postmenopausal women. Womens Health (Lond Engl) 2009;5(1):23-28
14. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289(24):3243-3253
15. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289(20):2673-2684
16. Seifert-Klauss V, Kingwell E, Hitchcock CL, et al. Estrogen and progestogen use in peri-and postmenopausal women. March 2007 position statement of The North American Menopause Society. Menopause 2007;14(2):168-182
17. Dennerstein L, Randolph J, Taffe J, et al. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77(Suppl 4):S42-8
18. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59(3):551-555
19. Rotter JI, Wong FL, Lifrak ET, Parker LN. A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism 1985;34(8):731-736
20. Crawford S, Santoro N, Laughlin GA, et al. Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab 2009;94(8):2945-2951
21. Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82(8):2396-2402
22. Basson R. Female sexual dysfunction in hypopituitarism. Lancet 2007;370(9589):737, 738
23. Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118(6):793-798
24. Nathorst-Boos J, von Schoultz B, Carlstrom K. Effective ovarian removal and estrogen replacement therapy-effects on sexual life, physchological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14(4):283-293
25. van der Stege JG, Groen H, van Zadelhoff SJ. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15(1):23-31
26. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343(10):682-688
27. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized tiral. Obstet Gynecol 2005;105(5Pt l):944-952
28. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90(9):5226-5233
29. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005:165(14):1571-1572
30. Davis SR, van der Mooren MJ, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;(3):387-396
31. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006:13(5):770-779
32. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359(19):2005-2017
33. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int J Fertil Menopausal Stud 1993;38(1):5-11
34. Reginster JY, Donazzolo Y, Brion N, Lins R. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches. Climacteric 2000;3(3):168-175
35. Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1995;173(3 Pt2):998-1004
36. Simon Ja, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;109(3):588-596
37. Buster JE, Koltun WD, Pascual ML, et al. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111(6):1343-1351
38. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996;23(2):209-216
39. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75(5):898-915
40. Georgiadou P, Sbarouni E. Effect of hormone replacement therapy on inflammatory biomarkers. Adv Clin Chem 2009;47:59-93
41. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36(6):1797-1802
42. Chu MC, Cosper P, Nakhuda GS, Lobo RA. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006;86(6):1669-1675
43. Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Datatabase Syst Rev. 2000;(2)CD001018
44. Di Carlo C, Tommaselli GA, Sammartino A, et al. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 2004;11(4):466-473
45. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333
46. Lokkegaard E, Andreasen AH, Jacobsen RK, et al. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29(21):2660-2668
47. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007:115(7):840-845
48. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005;112(22):3495-3500
49. Canonico M, Oger E, Conrad, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006;4(6):1259-1265
50. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 1974;39(2):340-346
51. Labrie F, Luu-The V, Bélanger A, et al. Is dehydroepiandrosterone a hormone? J Endocrinol 2005;187(2):169-196
52. Seibel M. Men, women and testosterone: why did the FDA fail Intrinsa? Sex Reprod Menopause 2005;(1):1-2
53. Kronawitter D, Gooren L, Zoliver H, et al. Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. Eur J Endocrinol 2009. [Epub ahead of print]
54. Nathorst-Boos J, Floter A, Jarkander-Rolff M, et al. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and phychological general well-being. Maturitas 2006;53(1):11-18
55. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on post menopausal bone density and sexuality. Maturitas 2008;61(1-2):17-26
56. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995:21(3):227-236
57. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47(4):339-351
58. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49(4):397-409
59. Wierman ME, Basson R, Davis Sr, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91(10):3697-3710
60. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopaus Society. Menopause 2005;13(5):496-511
61. Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63(1):63-66
62. Shufelt CL, Braunstein GD. Testosterone and the breast. Menopause Int 2008;14(3):117-122
63. Traish A, Guay AT, Spark RF. Testosterone Therapy in Women Study Group. Are the Encocrine Society's clinical practice guidelines on androgen therapy in women misguided? A commentary. J Sex Med 2007;4(5):1223-34, discussion 1234-1235
64. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in post menopausal women. Climacteric 2008;11(3):181-191
65. Kingsberg SA, Simon JA, Goldstein I. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2008;5(Suppl 4):182-193
66. Braunstein GD. The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: another one of Yogi's forks. J Clin Endocrinol Metab 2007;92(11):4091- 4093
67. van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62(1):76-80